...
首页> 外文期刊>Psychoneuroendocrinology: An International Journal >Associations of histories of depression and PMDD diagnosis with allopregnanolone concentrations following the oral administration of micronized progesterone.
【24h】

Associations of histories of depression and PMDD diagnosis with allopregnanolone concentrations following the oral administration of micronized progesterone.

机译:口服微粉化孕酮后,抑郁症和PMDD诊断史与别洛帕那诺酮浓度相关。

获取原文
获取原文并翻译 | 示例

摘要

Twenty-three women with premenstrual dysphoric disorder (PMDD) and 29 non-PMDD controls were compared for plasma progesterone (P) and its neuroactive steroid metabolite allopregnanolone (ALLO), as well as the ALLO/P ratio following the double-blind, placebo controlled administration of 300 mg oral micronized progesterone. Approximately half of each group had prior depression (DEP) (13 PMDD, 12 non-PMDD), though all were free of current depression. Progesterone and ALLO were sampled 160, 190, 225, and 255 min after progesterone administration. Changes over time in plasma concentrations and the ALLO/P ratio were assessed using area under the curve analyses. Women with prior DEP had lower ALLO levels (p=0.05) and marginally lower P levels (p<0.07) following progesterone administration compared to never depressed women, and this was especially evident in the non-PMDD women (p<0.01). PMDD women with no prior DEP had higher pre-progesterone ALLO/P ratios than all other groups (Ps<0.05) and higher ratios thanthe never depressed, non-PMDD women following oral progesterone (p<0.05). Results could not be accounted for by group differences in steroid hormone binding protein concentrations. For all women, progesterone administration was associated with increased confusion, fatigue, and with reduced confidence (Ps<0.01), even after controlling for placebo-associated mood change. These results suggest a persistent effect of prior DEP on P and ALLO concentrations following oral progesterone and that PMDD women, especially those with no prior DEP, may have alterations in the metabolic pathways underlying the conversion of P to ALLO.
机译:比较了23名经前烦躁不安(PMDD)和29名非PMDD对照女性的血浆孕酮(P)及其神经活性类固醇代谢物allopregnanolone(ALLO),以及双盲安慰剂后的ALLO / P比值控制口服300 mg微粒化的孕酮。每个组中大约有一半患有先前的抑郁症(DEP)(13 PMDD,12非PMDD),尽管所有患者都没有当前的抑郁症。孕酮给药后160、190、225和255分钟采集孕酮和ALLO。使用曲线分析下的面积评估血浆浓度和ALLO / P比值随时间的变化。与从未抑郁的女性相比,接受过DEP治疗的女性在服用黄体酮后的ALLO水平较低(p = 0.05),而P水平较低(p <0.07),这在非PMDD妇女中尤为明显(p <0.01)。没有进行过DEP治疗的PMDD妇女的孕前孕酮ALLO / P比值高于所有其他组(Ps <0.05),并且比接受口服孕酮治疗的从未抑郁,非PMDD妇女的比率更高(p <0.05)。结果不能通过类固醇激素结合蛋白浓度的组差异来解释。对于所有妇女,即使在控制了安慰剂相关的情绪变化后,孕激素的给药仍会增加混乱,疲劳和信心降低(Ps <0.01)。这些结果表明,口服口服孕酮后,先前的DEP对P和ALLO浓度具有持续影响,并且PMDD妇女,尤其是那些没有先前DEP的女性,可能在P转化为ALLO的代谢途径中发生改变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号